Laboratory:Akiruno
Laboratory:Akiruno
○circulatory drug
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
BLOOD COLLECTION TIME |
---|---|---|---|---|---|---|---|---|
|
Serum
0.5 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
Vanishing phase concentration 0.8-2.0 (ng/mL) | 6 hours after administration to immediately before next administration (disappearance phase) | |
Amiodarone
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
(ng/mL) | Immediately before next administration (Trough concentration) | |
Bepridil
|
Plasma
0.3 |
PH5 ↓ A00 |
(21 days) |
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
250-800(ng/mL) | ||
Aprindine
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
0.25-1.25(μg/mL) | Oral: Immediately before the next dose (Trough concentration) 2 to 4 hours after administration (Peak concentration) Intravenous injection: Immediately before the next dose (Trough concentration) | |
Aprindine
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
0.25-1.25(μg/mL) | Oral: Immediately before the next dose (Trough concentration) 2 to 4 hours after administration (Peak concentration) Intravenous injection: Immediately before the next dose (Trough concentration) | |
Disopyramide
|
Serum
0.3 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
2.0-5.0(μg/mL) | Immediately before next administration (Trough concentration) | |
Disopyramide
|
Plasma
0.3 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
2.0-5.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Serum
0.3 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
1.2-5.0(μg/mL) | Intravenous infusion: 2 hours after administration Intravenous infusion: 6 to 12 hours | |
Mexilethine
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
0.5-2.0(μg/mL) | Oral: Immediately before the next dose (Trough concentration) Intravenous injection: As needed | |
|
Serum
0.4 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
4.0-10.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.4 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
4.0-10.0(μg/mL) | Immediately before next administration (Trough concentration) | |
Propranolol
|
Serum
0.3 |
S7P ↓ A00 |
|
Please contact us in advance. |
HPLC HPLC (High performance liquid chromatography) |
50-100(ng/mL) | Immediately before next administration (Trough concentration) | |
Propranolol
|
Plasma
0.3 |
PH5 ↓ A00 |
|
Please contact us in advance. |
HPLC HPLC (High performance liquid chromatography) |
50-100(ng/mL) | Immediately before next administration (Trough concentration) | |
Pirsicainide
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
0.2-0.9(μg/mL) | Immediately before next administration (Trough concentration) | |
Pirsicainide
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
0.2-0.9(μg/mL) | Immediately before next administration (Trough concentration) | |
Propafenone
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
(ng/mL) | ||
Cibenzoline
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
Trough concentration 70-250(ng/mL) | Immediately before morning administration (Trough concentration) | |
Cibenzoline
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
Trough concentration 70-250(ng/mL) | Immediately before morning administration (Trough concentration) | |
Pirmenol
|
Plasma
1.3 |
PH5 ↓ A00 |
|
3-9 |
HPLC HPLC (High performance liquid chromatography) |
400.0 or less (ng/mL) | at any time | |
Quinidine
|
Serum
0.4 |
S7P ↓ A00 |
|
2-8 |
KIMS KIMS (Kinetic Interaction of Microparticles in Solution) |
2.0-6.0(μg/mL) | Immediately before next administration (Trough concentration) | |
Quinidine
|
Plasma
0.4 |
PH5 ↓ A00 |
|
2-8 |
KIMS KIMS (Kinetic Interaction of Microparticles in Solution) |
2.0-6.0(μg/mL) | Immediately before next administration (Trough concentration) | |
Flecainide
|
Serum
0.3 |
S7P ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
200-1000(ng/mL) | Immediately before next administration (Trough concentration) | |
Flecainide
|
Plasma
0.3 |
PH5 ↓ A00 |
|
3-5 |
LC/MS/MS LC/MS/MS (Liquid chromatography tandem mass spectrometry) |
200-1000(ng/mL) | Immediately before next administration (Trough concentration) | |
|
Serum
0.4 |
S7P ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme Immunoassay Assay) |
6.0-20.0(μg/mL) | Immediately before next administration (Trough concentration) | |
|
Plasma
0.4 |
PH5 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme Immunoassay Assay) |
6.0-20.0(μg/mL) | Immediately before next administration (Trough concentration) |